Table 4. Clinical characteristics of 500 uveitis-affected eyes with and without serous retinal detachment.
| Total(n=500) | WITH serous retinal detachment | WITHOUT serous retinal detachment | P-valuea | |
|---|---|---|---|---|
| (n=40) | (n=460) | |||
| Age at onset (years) | 0.075b | |||
| Mean±SD (range) | 45±19 (1–90) | 50±17 (6–79) | 44±19 (1–90) | |
| 0–15, n (%) | 32 (6%) | 1 (3%) | 31 (7%) | |
| 16–24, n (%) | 33 (7%) | 2 (5%) | 31 (7%) | |
| 25–44, n (%) | 189 (38%) | 9 (22%) | 180 (39%) | |
| 45–64, n (%) | 161 (32%) | 19 (48%) | 142 (31%) | |
| ≥65, n (%) | 85 (17%) | 9 (22%) | 76 (16%) | |
| Gender | 0.967c | |||
| Female, n (%) | 278 (56%) | 23 (57%) | 255 (55%) | |
| Male, n (%) | 222 (44%) | 17 (43%) | 205 (45%) | |
| Onset of uveitis | 0.604c | |||
| Sudden, n (%) | 319 (64%) | 23 (57%) | 296 (64%) | |
| Insidious, n (%) | 181 (36%) | 17 (43%) | 164 (36%) | |
| Duration of an attack of uveitis | 0.273c | |||
| Limitedd, n (%) | 318 (64%) | 21 (53%) | 297 (65%) | |
| Persistente, n (%) | 182 (36%) | 19 (47%) | 163 (35%) | |
| Course of uveitis | 0.273c | |||
| Acutef, n (%) | 89 (18%) | 7 (18%) | 82 (18%) | |
| Recurrentg, n (%) | 237 (47%) | 14 (35%) | 223 (48%) | |
| Chronich, n (%) | 174 (35%) | 19 (47%) | 155 (34%) | |
| Type of inflammation | 0.162c | |||
| Granulomatous, n (%) | 74 (15%) | 10 (25%) | 64 (14%) | |
| Nongranulomatous, n (%) | 426 (85%) | 30 (75%) | 396 (86%) | |
| Laterality of uveitis | 0.840c | |||
| Unilateral, n (%) | 220 (44%) | 16 (40%) | 204 (44%) | |
| Bilateral, n (%) | 280 (56%) | 24 (60%) | 256 (56%) | |
| BSCVA (Snellen) | <0.001b | |||
| Mean±SD (range) | 0.60±0.35 (0–1.6) | 0.22±0.21 (0–0.8) | 0.63±0.34 (0–1.6) | |
| <0.1, n (%) | 39 (8%) | 11 (28%) | 28 (6%) | |
| 0.1–0.4, n (%) | 150 (30%) | 24 (60%) | 126 (27%) | |
| 0.5–1.0, n (%) | 293 (59%) | 5 (12%) | 288 (63%) | |
| >1.0, n (%) | 18 (4%) | — | 18 (4%) | |
| Etiology of uveitis | 0.032c | |||
| Infectious uveitis, n (%) | 74 (15%) | 10 (25%) | 64 (14%) | |
| Specific clinical entity, n (%) | 124 (25%) | 3 (8%) | 121 (26%) | |
| Uveitis associated with systemic disease, n (%) | 82 (16%) | 10 (25%) | 72 (16%) | |
| Idiopathic uveitis, n (%) | 220 (44%) | 17 (42%) | 203 (44%) |
Abbreviation: BSCVA, best spectacle-corrected visual acuity (Snellen).
a
Corrected for multiple testing (Benjamini–Hochberg).
b
Mann–Whitney U-test.
c
χ2-test.
d
≤3 months duration.
e
>3 months duration.
f
Episode characterized by sudden onset and limited duration.
g
Repeated episodes separated by periods of inactivity without treatment ≥3 months in duration.
h
Persistent uveitis with relapse in <3 months after discontinuing treatment.